Its key for strong bones, a healthy immune system, and even your mood
Privacy Policy/California Privacy Notice

Anti-obesity medication semaglutide (Wegovy) could benefit millions of Americans with obesity and cardiovascular disease, Yale Medicine (2023) FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight, FDA (2024) FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014, FDA (2021) FDA approves Ozempic for cardiovascular risk reduction in adults with type 2 diabetes and known heart disease, updates Rybelsus label, Novo Nordisk (2020) Heart disease facts, CDC (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, New England Journal of Medicine (2023) Updates about Wegovy, Novo Nordisk (2024) Wegovy approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease, Novo Nordisk (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Diabetes mellitus was also found to be associated with an increase of more than twofold in the risk of ulcer formation after DVT 155
Weekly dosing means 52 injections per year instead of 365